Online ISSN: 3007-0244,
Print ISSN:  2410-4280
ХИРУРГИЯЛЫҚ ЖӘНЕ ТРАВМАТОЛОГИЯЛЫҚ ТӘЖІРИБЕДЕ ВЕНОЗДЫҚ ТРОМБОЭМБОЛИЯ. ӘДЕБИ ШОЛУ
Автор (лар): Исаханова С.А
Өзектілігі: Бүкіл әлемдегі барлық өлімдердің себептері арасында - веналық тромбоэмболия үшінші орында орналасқан. Мәселеге үлкен көңіл аударғанмен веналық тромбоэмболия ауырлығы, оны кез-келген патология басталуына дейін (онкология, хирургия, босану және басқалар) алдын ала жүргізілген диагностикалық шаралар кезінде анықтау жиілігі өте төмен. Сонымен қатар, бұл патология кезінде арнайы емес жүргізілген іс-әрекеттер нәтижесі төмен, өлім және әр түрлі жақын не алыстаған асқынулар дамуы жиілігі жоғары. Жас және орта жастағы науқастарда басқа негізгі себептер болмаған кезде, веноздық тромбоз және өлімге әкелетін негізгі себептерінің бірі - ұзақ және ауқымды хирургиялық араласулар және травматологиялық операциялар болып саналады. Жұмыс мақсаты: Шолудың негізгі мақсаты хирургиялық және травматологиялық араласулар кезінде, веноздық тромбоздың алдын алу, емдеу және даму механизмдерін зерттеу туралы замануи ақпарат көздерін іздеу болып табылады. Іздеу әдістері: PubMed, Medline, Scopus, Trip Database деректер базаларында 7 жыл аралығында шығарылған «веноздық тромбоэмболия», «хирургиядағы веноздық тромбоэмболия», «травматологиядағы веноздық тромбоэмболия», «веноздық тромбоэмболияны алдын-алу», «веноздық тромбоэмболияны емдеу», «веноздық тромбоэмболияның салдары» атты түйінді сөздеріне жауап алу нәтижесінде, алынған бастапқы зерттеулердің, клиникалық зерттеулердің, оның ішінде бақыланатын және рандомизацияланған, жүйелі шолулар мен мета-анализдердің нәтижелерін зерттедік. Хирургиялық тәжирибедегі тромбоэмболияның диагностикасының және емінің заманауи жолдарын анықтайтын баспалар еңгізу критериялары болып табылды, сонымен бірге, акушерлік патология, онкология, жүрек-қантамыр жүйесінің аурулары кезінде тромбоэмболияны баяндайтын баспалар, іздеуден алынды. 782 табылған мақалалардан соңғы зерттеуге 59-ы кірді. Зерттеу нәтижесі: Веноздық тромбоэмболияның алдын-алу және емдеудің заманауи нұсқаулары, оны тестке дейінгі бағалау шкаласы түрінде қарастырады. Сонымен қатар, бұл шкала тәжирибеде тромбоз қаупі жоғары пациенттер тобын анықтауға әр түрлі шкалалардың ішінде негізгі түрінде қолдануға ұсынылады. Алдыңғы онжылдықтарда, басталған тромбоз критерияларын анықтау мақсатымен жиі қолданылатын тесттердің өзектілігі жоғалғанын ескере отырып, оларды қолдануды тоқтату керек. Тәжірибеде жаңа дәрі-дәрмектердің қолданылуына байланысты, медикаментозды терапияның тәсілдері де өзгеруі керек
Сауле А. Исаханова, https://orcid.org/0000-0001-5231-3891 Госпитальды терапия кафедрасы, КеАҚ «Семей медициналық университеті», Семей қаласы, Қазақстан Республикасы.
1. Бабак О.Я., Мясоедов В.В., Молодан В.И., Просоленко К.А., Гапонова О.Г. Влияние розувастатина и фенофибрата на эхокардиографические и биохи-мические показатели эндотелиальной реактивности в зависимости от полиморфизма генов PPARG и PPARА у больных гипертонической болезнью с ожирением // Новый армянский медицинский журнал. 2016. № 1. С. 87-93. 2. Бапаева Г.Б., Жумадилов Ж.Ш., Чириков М.Н. Способ лечения синдрома задержки внутриутробного развития плода // 15.10.2014 - IP 29001 - База патентов Казахстана. Казахстан, 2014. С. 5. 3. Гусина А.А., Гусина Н.Б. Генетические дефекты про- и антикоагулянтных белков как факторы риска венозных тромбозов // Медицинские новости. 2006. № 9. С. 10–14. 4. Мяленка Е.В., Яблонский П.К., Веселкин Н.П. Генетически опосредованные факторы риска тромбозов глубоких вен и тромбоэмболии легочной артерии (обзор литературы и собственные данные) // Вестник СПбГУ. 2012. № 1. С.35-42. 5. Макацария, А.Д.; Абрамян Р.А. Система протеина С и патологические состояния организма, в частности в акушерской практике // Медицинская наука Армении НАН РА. 2013. Vol. LIII, № 4. С. 8–20. 6. Филлипова О.И., Колосков А.В. Риски тромботи-ческих осложнений в хирургии // Вестник хирургии имени И. И. Грекова. 2017. Том 2. № 176. С. 119-122. 7. Ageno W., Squizzato A., Wells P.S., Büller H.R., Johnson G. The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH // J. Thromb. Haemost. John Wiley & Sons, Ltd, 2013. Vol. 11, № 8. P. 1597–1602. 8. Albertsen I.E., Goldhaber S.Z., Piazza G., Overvad T.F., Nielsen P.B., Larsen T.B. et al. Predictors of not initiating anticoagulation after incident venous thromboembolism: a Danish nationwide cohort study // The American Journal of Medicine. Elsevier BV, 2019. 9. Avan A., Tavakoly Sany S.B., Ghayour-Mobarhan M., Rahimi H.R., Tajfard M., Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice // Journal of Cellular Physiology. Wiley-Liss Inc., 2018. Vol. 233, № 11. P. 8508–8525. 10. Balk E., Ellis A., Mengyang D., Adam G., Trikalinos T. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update // Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. 2017. № 191. 11. Bartholomew J.R. Update on the management of venous thromboembolism. // Cleve. Clin. J. Med. 2017. Vol. 84, № 12 Suppl 3. P. 39–46. 12. Bartholomew J.R., Evans N.S. Travel-related venous thromboembolism // Vascular Medicine (United Kingdom). SAGE Publications Ltd, 2019. Vol. 24, № 1. P. 93–95. 13. Boddi M., Peris A. Deep Vein Thrombosis in Intensive Care. // Adv. Exp. Med. Biol. Springer New York LLC, 2017. Vol. 906. P. 167–181. 14. Cohen A.T., Hamilton M., Mitchell S.A., Phatak H., Liu X., Bird A., et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis // PLoS One. Public Library of Science, 2015. Vol. 10, № 12. 15. Curto‐Garcia N., Doyle A.J., Breen K.A., McLornan D.P., Radia D.H., Hunt B.J., et al. Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK // Br. J. Haematol. John Wiley & Sons, Ltd, 2020. 16. Czaplicki C., Albadawi H., Partovi S., Gandhi R.T., Quencer K., Deipolyi A.R., et al. Can thrombus age guide thrombolytic therapy? // Cardiovascular Diagnosis and Therapy. AME Publishing Company, 2017. Vol. 7, № Suppl 3. P. S186–S196. 17. Dahlbäck B. Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation // Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers, Inc., 1999. Vol. 25, № 3. P. 273–289. 18. Elsebaie M.A.T., Es van N., Langston A., Büller H.R., Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis // J. Thromb. Haemost. Blackwell Publishing Ltd, 2019. Vol. 17, № 4. P. 645–656. 19. Feng J.P., Xiong Y.T., Fan Z.Q., Yan L.J., Wang J.Y., Gu Z.J. Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis // Oncotarget. Impact Journals LLC, 2017. Vol. 8, № 12. P. 20371–20379. 20. Forster R., Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2016. Vol. 2016, № 3. 21. Gal G. Le, Righini M. Preface to Diagnosis of venous thromboembolism // Thrombosis Research. Elsevier Ltd, 2018. Vol. 163. P. 200. 22. Guideline Quick View: Venous Thromboembolism // AORN J. NLM (Medline), 2018. Vol. 107, № 2. P. 281–285. 23. Hajibandeh S., Hajibandeh S., Antoniou G.A., Scurr J.R.H., Torella F. Neuromuscular electrical stimulation for the prevention of venous thromboembolism // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 11. 24. Heit J.A., Crusan D.J., Ashrani A.A., Petterson T.M., Bailey K.R. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US // Blood. American Society of Hematology, 2017. Vol. 130, № 2. P. 109–114. 25. Hickey B.A., Watson U., Cleves A., Alikhan R., Pugh N., Nokes L., et al. Does thromboprophylaxis reduce symptomatic venous thromboembolism in patients with below knee cast treatment for foot and ankle trauma? A systematic review and meta-analysis // Foot and Ankle Surgery. Elsevier Ltd, 2018. Vol. 24, № 1. P. 19–27. 26. Hillis C.M., Crowther M.A. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants // Thromb. Haemost. Schattauer GmbH, 2015. Vol. 113, № 6. P. 1193–1201. 27. Hur M., Park S.K., Koo C.H., Jung E.D., Kang P., Kim W.H., et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty: A network meta-analysis // Acta Orthop. Taylor and Francis Ltd, 2017. Vol. 88, № 6. P. 634–641. 28. Kahn S.R., Morrison D.R., Diendéré G., Piché A., Filion K.B., Klil-Drori A.J., et al. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2018. Vol. 2018, № 4. 29. Kapoor A., Ellis A., Shaffer N., Gurwitz J., Chandramohan A., Saulino J., et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis // J. Thromb. Haemost. Blackwell Publishing Ltd, 2017. Vol. 15, № 2. P. 284–294. 30. Kearon C., Ageno W., Cannegieter S.C., Cosmi B., Geersing G.J., Kyrle P.A. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH // J. Thromb. Haemost. Blackwell Publishing Ltd, 2016. Vol. 14, № 7. P. 1480–1483. 31. Khan F., Rahman A., Carrier M., Kearon C., Weitz J..I, Schulman S., et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: Systematic review and meta-analysis // BMJ. BMJ Publishing Group, 2019. Vol. 366. 32. Le Gal G., Righini M., Wells P.S. Scoring Systems for Diagnosis of Acute Venous Thromboembolism // Semin. Thromb. Hemost. Thieme Medical Publishers, Inc., 2017. Vol. 43, № 5. P. 479–485. 33. Lee L.H., Gallus A., Jindal R., Wang C., Wu C.C. Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review // Thrombosis and Haemostasis. Georg Thieme Verlag, 2017. Vol. 117, № 12. P. 2243–2260. 34. Lee Y.H., Song G.G. Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis // Rheumatol. Int. Springer Verlag, 2017. Vol. 37, № 7. P. 1165–1173. 35. Lewis S., Glen J., Dawoud D., Dias S., Cobb J., Griffin X.L., et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis // Lancet Haematol. Elsevier Ltd, 2019. Vol. 6, № 10. P. e530–e539. 36. Linnemann B., Hart C. Laboratory Diagnostics in Thrombophilia // Hamostaseologie. Georg Thieme Verlag, 2019. Vol. 39, № 1. P. 49–61. 37. Lippi G., Plebani M., Favaloro E.J. The changing face of hemostasis testing in modern laboratories: Consolidation, automation, and beyond // Semin. Thromb. Hemost. Thieme Medical Publishers, Inc., 2015. Vol. 41, № 3. P. 294–299. 38. Milinis K., Shalhoub J., Coupland A.P., Salciccioli J.D., Thapar A., Davies A.H. The effectiveness of graduated compression stockings for prevention of venous thromboembolism in orthopedic and abdominal surgery patients requiring extended pharmacologic thromboprophylaxis // Journal of Vascular Surgery: Venous and Lymphatic Disorders. Elsevier Inc., 2018. Vol. 6, № 6. P. 766-777. 39. Miller B.J., Yang R., Geller D.S., Hoang B.H. Epidemiology, Therapeutic Strategies, Outcomes, and Complications of Pathologic Fractures. // Instr. Course Lect. 2019. Vol. 68. P. 567–576. 40. Moubayed S.P., Eskander A., Mourad M.W., Most S.P. Systematic review and meta-analysis of venous thromboembolism in otolaryngology–head and neck surgery // Head and Neck. John Wiley and Sons Inc., 2017. Vol. 39, № 6. P. 1249–1258. 41. Moussaoui S., Saussoy P., Ambroise J., Defour J.P., Zouitene R., Sifi K., et al. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population // Clinical and Applied Thrombosis/Hemostasis. SAGE Publications Inc., 2017. Vol. 23, № 2. P. 105–115. 42. Pannucci C.J., Swistun L., MacDonald J.K., Henke P.K., Brooke B.S. Individualized venous thromboembolism risk stratification using the 2005 caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: A meta-analysis // Ann. Surg. Lippincott Williams and Wilkins, 2017. Vol. 265, № 6. P. 1094–1103. 43. Pavon J.M., Adam S.S., Razouki Z.A., McDuffie J.R., Lachiewicz P.F., Kosinski A.S., et al. Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review // Journal of Arthroplasty. Churchill Livingstone Inc., 2016. Vol. 31, № 2. P. 524–532. 44. Pezeshkpoor B., Castoldi E., Mahler A., Hanel D., Müller J., Hamedani N.S., et al. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance // J. Thromb. Haemost. Blackwell Publishing Ltd, 2016. Vol. 14, № 7. P. 1353–1363. 45. Pollak A.W., McBane R.D. Succinct review of the new VTE prevention and management guidelines // Mayo Clinic Proceedings. Elsevier Ltd, 2014. Vol. 89, № 3. P. 394–408. 46. Puurunen M.K., Gona P.N., Larson M.G., Murabito J.M., Magnani J.W., O’Donnell C.J. Epidemiology of venous thromboembolism in the Framingham Heart Study // Thromb. Res. Elsevier Ltd, 2016. Vol. 145. P. 27–33. 47. Raskob G.E., Angchaisuksiri P., Blanco A.N., Buller H., Ddungu H., Hunt B.J., et al. Venous thromboembolism: A call for risk assessment in all hospitalised patients // Thromb. Haemost. Schattauer GmbH, 2016. Vol. 116, № 5. P. 777–779. 48. Robertson L., Yeoh S.E., Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 12. 49. Schulman S., Ageno W., Konstantinides S. V. Venous thromboembolism: Past, present and future // Thromb. Haemost. Schattauer GmbH, 2017. Vol. 117, № 7. P. 1219–1229. 50. Sterne J.A.C., Bodalia P.N., Bryden P.A., Davies P.A., López-López J.A., Okoli G.N., et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis and cost-effectiveness analysis // Health Technology Assessment. NIHR Journals Library, 2017. Vol. 21, № 9. P. 1–385. 51. Stuck A.K., Spirk D., Schaudt J., Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: A systematic review // Thromb. Haemost. Schattauer GmbH, 2017. Vol. 117, № 4. P. 801–808. 52. Tan T.L., Foltz C., Huang R., Chen A.F., Higuera C., Siqueira M., et al. Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients // J. Bone Jt. Surg. - Am. Vol. Lippincott Williams and Wilkins, 2019. Vol. 101, № 7. P. 589–599. 53. Tang L., Wu Y.Y., Lip G.Y.H., Yin P., Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis // Lancet Haematol. Elsevier Ltd, 2016. Vol. 3, № 1. P. e30–e44. 54. Timerbulatov V.M., Sakhautdinov V.G., Timerbulatov S. V., Smyr RA, Sargsyan A.M. Acute disorders of mesenteric circulation // Endosk. khirurgiya. Media Sphere Publishing Group, 2016. Vol. 22, № 3. P. 44. 55. Vasanthamohan L., Boonyawat K., Chai-Adisaksopha C., Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis // J. Thromb. Haemost. Blackwell Publishing Ltd, 2018. Vol. 16, № 7. P. 1288–1295. 56. Venclauskas L., Maleckas A., Arcelus J.I. European guidelines on perioperative venous thromboembolism prophylaxis // Eur. J. Anaesthesiol. Lippincott Williams and Wilkins, 2018. Vol. 35, № 2. P. 147–153. 57. Wang J., Wang C., Chen N., Shu C., Guo X., He Y., et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: A meta-analysis // Thromb. Res. Elsevier Ltd, 2014. Vol. 134, № 6. P. 1241–1248. 58. Wei W.-T., Liu P.P.-S., Lin S.-M., Peng C.C.-H., Wang J.-H., Huang H.-K., et al. Hypothyroidism and the Risk of Venous Thromboembolism: A Nationwide Cohort Study // Thromb. Haemost. Georg Thieme Verlag KG, 2020. 59. Wells P.S., Tritschler T., Kraaijpoel N., Le Gal G. Venous Thromboembolism: Advances in Diagnosis and Treatment // JAMA - J. Am. Med. Assoc. American Medical Association, 2018. Vol. 320, № 15. P. 1583–1594. References: 1. Babak O.Ja., Mjasoedov V.V., Molodan V.I., Prosolenko K.A., Gaponova O.G. Vliyanie rozuvastatina i fenofibrata na ekhokardiograficheskie i biokhimicheskie pokazateli endotelial'noi reaktivnosti v zavisimosti ot polimorfizma genov PPARG i PPARA u bol'nykh gipertonicheskoi boleznyu s ozhireniem [The effect of rosuvastatin and fenofibrate on echocardiographic and biochemical indices of endothelial reactivity depending on the polymorphism of the PPARG and PPARA genes in obese hypertensive patients]. Novyi armyanskii meditsinskii zhurnal [New Armenian Medical Journal]. 2016. № 1. pp. 87-93. [in Russian] 2. Bapaeva G.B., Zhumadilov Zh.Sh., Chirikov M.N. Sposob lechenija sindroma zaderzhki vnutriutrobnogo razvitija ploda [A method for the treatment of intrauterine growth retardation syndrome]. 15.10.2014 - IP 29001 - Baza patentov Kazahstana. Kazakhstan [The Base of patents of Kazakhstan]. 2014. pp. 5. [in Russian] 3. Gusina A.A., Gusina N.B. Geneticheskie defekty pro- i antikoaguljantnyh belkov kak faktory riska venoznyh trombozov [Genetic defects and anticoagulant proteins as risk factors for venous thrombosis]. Medicinskie Novosti [The Medical News]. 2006. № 9. pp. 10–14. [in Russian] 4. Mjalenka E.V., Jablonskij P.K., Veselkin N.P. Geneticheski oposredovannye faktory riska trombozov glubokih ven i trombojembolii legochnoj arterii (obzor literatury i sobstvennye dannye) [Genetically mediated risk factors for deep vein thrombosis and pulmonary thromboembolism (literature review and own data)]. Vestnik SPbGU [The Bulletin of St. Petersburg State University]. 2012. № 1, pp.35-42 [in Russian] 5. Makacarija, A.D.; Abramjan R.A. Sistema proteina S i patologicheskie sostojanija organizma, v chastnosti v akusherskoj praktike [Protein C system and pathological conditions of the body, in particular in obstetric practice]. Medicinskaja nauka Armenii NAN RA [Medical Science of Armenia NAS RA]. 2013. Vol. LIII, № 4. pp. 8–20. [in Russian] 6. Fillipova O.I., Koloskov A.V. Riski tromboticheskih oslozhnenij v hirurgii [Risks of thrombotic complications in surgery]. Vestnik hirurgii imeni I.I. Grekova [Bulletin of Surgery named after I. I. Grekov]. 2017. Tom 2. № 176. pp. 119-122. [in Russian] 7. Ageno W., Squizzato A., Wells P.S., Büller H.R., Johnson G. The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTHю. J. Thromb. Haemost. John Wiley & Sons, Ltd, 2013. Vol. 11, № 8. P. 1597–1602. 8. Albertsen I.E., Goldhaber S.Z., Piazza G., Overvad T.F., Nielsen P.B., Larsen T.B. et al. Predictors of not initiating anticoagulation after incident venous thromboembolism: a Danish nationwide cohort study. The American Journal of Medicine. Elsevier BV, 2019. 9. Avan A., Tavakoly Sany S.B., Ghayour-Mobarhan M., Rahimi H.R., Tajfard M., Ferns G. Serum C-reactive protein in the prediction of cardiovascular diseases: Overview of the latest clinical studies and public health practice. Journal of Cellular Physiology. Wiley-Liss Inc., 2018. Vol. 233, № 11. P. 8508–8525. 10. Balk E., Ellis A., Mengyang D., Adam G., Trikalinos T. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update. 2017. № 191. 11. Bartholomew J.R. Update on the management of venous thromboembolism. Cleve. Clin. J. Med. 2017. Vol. 84, № 12 Suppl 3. P. 39–46. 12. Bartholomew J.R., Evans N.S. Travel-related venous thromboembolism. Vascular Medicine (United Kingdom). SAGE Publications Ltd, 2019. Vol. 24, № 1. P. 93–95. 13. Boddi M., Peris A. Deep Vein Thrombosis in Intensive Care. Adv. Exp. Med. Biol. Springer New York LLC, 2017. Vol. 906. P. 167–181. 14. Cohen A.T., Hamilton M., Mitchell S.A., Phatak H., Liu X., Bird A., et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: Systematic review and network meta-analysis. PLoS One. Public Library of Science, 2015. Vol. 10, № 12. 15. Curto‐Garcia N., Doyle A.J., Breen K.A., McLornan D.P., Radia D.H., Hunt B.J., et al. Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UK. Br. J. Haematol. John Wiley & Sons, Ltd, 2020. 16. Czaplicki C., Albadawi H., Partovi S., Gandhi R.T., Quencer K., Deipolyi A.R., et al. Can thrombus age guide thrombolytic therapy? Cardiovascular Diagnosis and Therapy. AME Publishing Company, 2017. Vol. 7, № Suppl 3. P. S186–S196. 17. Dahlbäck B. Activated protein C resistance and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Seminars in Thrombosis and Hemostasis. Thieme Medical Publishers, Inc., 1999. Vol. 25, № 3. P. 273–289. 18. Elsebaie M.A.T., Es van N., Langston A., Büller H.R., Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J. Thromb. Haemost. Blackwell Publishing Ltd, 2019. Vol. 17, № 4. P. 645–656. 19. Feng J.P., Xiong Y.T., Fan Z.Q., Yan L.J., Wang J.Y., Gu Z.J. Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis. Oncotarget. Impact Journals LLC, 2017. Vol. 8, № 12. P. 20371–20379. 20. Forster R., Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2016. Vol. 2016, № 3. 21. Gal G. Le, Righini M. Preface to Diagnosis of venous thromboembolism. Thrombosis Research. Elsevier Ltd, 2018. Vol. 163. P. 200. 22. Guideline Quick View: Venous Thromboembolism. AORN J. NLM (Medline), 2018. Vol. 107, № 2. P. 281–285. 23. Hajibandeh S., Hajibandeh S., Antoniou G.A., Scurr J.R.H., Torella F. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 11. 24. Heit J.A., Crusan D.J., Ashrani A.A., Petterson T.M., Bailey K.R. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood. American Society of Hematology, 2017. Vol. 130, № 2. P. 109–114. 25. Hickey B.A., Watson U., Cleves A., Alikhan R., Pugh N., Nokes L., et al. Does thromboprophylaxis reduce symptomatic venous thromboembolism in patients with below knee cast treatment for foot and ankle trauma? A systematic review and meta-analysis. Foot and Ankle Surgery. Elsevier Ltd, 2018. Vol. 24, № 1. P. 19–27. 26. Hillis C.M., Crowther M.A. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thromb. Haemost. Schattauer GmbH, 2015. Vol. 113, № 6. P. 1193–1201. 27. Hur M., Park S.K., Koo C.H., Jung E.D., Kang P., Kim W.H., et al. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty: A network meta-analysis. Acta Orthop. Taylor and Francis Ltd, 2017. Vol. 88, № 6. P. 634–641. 28. Kahn S.R., Morrison D.R., Diendéré G., Piché A., Filion K.B., Klil-Drori A.J., et al. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2018. Vol. 2018, № 4. 29. Kapoor A., Ellis A., Shaffer N., Gurwitz J., Chandramohan A., Saulino J., et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J. Thromb. Haemost. Blackwell Publishing Ltd, 2017. Vol. 15, № 2. P. 284–294. 30. Kearon C., Ageno W., Cannegieter S.C., Cosmi B., Geersing G.J., Kyrle P.A. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J. Thromb. Haemost. Blackwell Publishing Ltd, 2016. Vol. 14, № 7. P. 1480–1483. 31. Khan F., Rahman A., Carrier M., Kearon C., Weitz J..I, Schulman S., et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: Systematic review and meta-analysis. BMJ. BMJ Publishing Group, 2019. Vol. 366. 32. Le Gal G., Righini M., Wells P.S. Scoring Systems for Diagnosis of Acute Venous Thromboembolism. Semin. Thromb. Hemost. Thieme Medical Publishers, Inc., 2017. Vol. 43, № 5. P. 479–485. 33. Lee L.H., Gallus A., Jindal R., Wang C., Wu C.C. Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review. Thrombosis and Haemostasis. Georg Thieme Verlag, 2017. Vol. 117, № 12. P. 2243–2260. 34. Lee Y.H., Song G.G. Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis. Rheumatol. Int. Springer Verlag, 2017. Vol. 37, № 7. P. 1165–1173. 35. Lewis S., Glen J., Dawoud D., Dias S., Cobb J., Griffin X.L., et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematol. Elsevier Ltd, 2019. Vol. 6, № 10. P. e530–e539. 36. Linnemann B., Hart C. Laboratory Diagnostics in Thrombophilia. Hamostaseologie. Georg Thieme Verlag, 2019. Vol. 39, № 1. P. 49–61. 37. Lippi G., Plebani M., Favaloro E.J. The changing face of hemostasis testing in modern laboratories: Consolidation, automation, and beyond. Semin. Thromb. Hemost. Thieme Medical Publishers, Inc., 2015. Vol. 41, № 3. P. 294–299. 38. Milinis K., Shalhoub J., Coupland A.P., Salciccioli J.D., Thapar A., Davies A.H. The effectiveness of graduated compression stockings for prevention of venous thromboembolism in orthopedic and abdominal surgery patients requiring extended pharmacologic thromboprophylaxis. Journal of Vascular Surgery: Venous and Lymphatic Disorders. Elsevier Inc., 2018. Vol. 6, № 6. P. 766-777. 39. Miller B.J., Yang R., Geller D.S., Hoang B.H. Epidemiology, Therapeutic Strategies, Outcomes, and Complications of Pathologic Fractures. Instr. Course Lect. 2019. Vol. 68. P. 567–576. 40. Moubayed S.P., Eskander A., Mourad M.W., Most S.P. Systematic review and meta-analysis of venous thromboembolism in otolaryngology–head and neck surgery. Head and Neck. John Wiley and Sons Inc., 2017. Vol. 39, № 6. P. 1249–1258. 41. Moussaoui S., Saussoy P., Ambroise J., Defour J.P., Zouitene R., Sifi K., et al. Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population. Clinical and Applied Thrombosis/Hemostasis. SAGE Publications Inc., 2017. Vol. 23, № 2. P. 105–115. 42. Pannucci C.J., Swistun L., MacDonald J.K., Henke P.K., Brooke B.S. Individualized venous thromboembolism risk stratification using the 2005 caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: A meta-analysis. Ann. Surg. Lippincott Williams and Wilkins, 2017. Vol. 265, № 6. P. 1094–1103. 43. Pavon J.M., Adam S.S., Razouki Z.A., McDuffie J.R., Lachiewicz P.F., Kosinski A.S., et al. Effectiveness of Intermittent Pneumatic Compression Devices for Venous Thromboembolism Prophylaxis in High-Risk Surgical Patients: A Systematic Review. Journal of Arthroplasty. Churchill Livingstone Inc., 2016. Vol. 31, № 2. P. 524–532. 44. Pezeshkpoor B., Castoldi E., Mahler A., Hanel D., Müller J., Hamedani N.S., et al. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVBonn) associated with activated protein C resistance. J. Thromb. Haemost. Blackwell Publishing Ltd, 2016. Vol. 14, № 7. P. 1353–1363. 45. Pollak A.W., McBane R.D. Succinct review of the new VTE prevention and management guidelines. Mayo Clinic Proceedings. Elsevier Ltd, 2014. Vol. 89, № 3. P. 394–408. 46. Puurunen M.K., Gona P.N., Larson M.G., Murabito J.M., Magnani J.W., O’Donnell C.J. Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb. Res. Elsevier Ltd, 2016. Vol. 145. P. 27–33. 47. Raskob G.E., Angchaisuksiri P., Blanco A.N., Buller H., et al. Venous thromboembolism: A call for risk assessment in all hospitalised patients. Thromb. Haemost. Schattauer GmbH, 2016. Vol. 116, № 5. P. 777–779. 48. Robertson L., Yeoh S.E., Ramli A. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 12. 49. Schulman S., Ageno W., Konstantinides S. V. Venous thromboembolism: Past, present and future. Thromb. Haemost. Schattauer GmbH, 2017. Vol. 117, № 7. P. 1219–1229. 50. Sterne J.A.C., Bodalia P.N., Bryden P.A., Davies P.A., López-López J.A., Okoli G.N., et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment. NIHR Journals Library, 2017. Vol. 21, № 9. P. 1–385. 51. Stuck A.K., Spirk D., Schaudt J., Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: A systematic review. Thromb. Haemost. Schattauer GmbH, 2017. Vol. 117, № 4. P. 801–808. 52. Tan T.L., Foltz C., Huang R., Chen A.F., Higuera C., Siqueira M., et al. Potent Anticoagulation Does Not Reduce Venous Thromboembolism in High-Risk Patients. J. Bone Jt. Surg. - Am. Vol. Lippincott Williams and Wilkins, 2019. Vol. 101, № 7. P. 589–599. 53. Tang L., Wu Y.Y., Lip G.Y.H., Yin P., Hu Y. Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. Elsevier Ltd, 2016. Vol. 3, № 1. P. e30–e44. 54. Timerbulatov V.M., Sakhautdinov V.G., Timerbulatov S. V., Smyr RA, Sargsyan A.M. Acute disorders of mesenteric circulation. Endosk. khirurgiya. Media Sphere Publishing Group, 2016. Vol. 22, № 3. P. 44. 55. Vasanthamohan L., Boonyawat K., Chai-Adisaksopha C., Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J. Thromb. Haemost. Blackwell Publishing Ltd, 2018. Vol. 16, № 7. P. 1288–1295. 56. Venclauskas L., Maleckas A., Arcelus J.I. European guidelines on perioperative venous thromboembolism prophylaxis. Eur. J. Anaesthesiol. Lippincott Williams and Wilkins, 2018. Vol. 35, № 2. P. 147–153. 57. Wang J., Wang C., Chen N., Shu C., Guo X., He Y., et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: A meta-analysis. Thromb. Res. Elsevier Ltd, 2014. Vol. 134, № 6. P. 1241–1248. 58. Wei W.-T., Liu P.P.-S., Lin S.-M., Peng C.C.-H., Wang J.-H., Huang H.-K., et al. Hypothyroidism and the Risk of Venous Thromboembolism: A Nationwide Cohort Study. Thromb. Haemost. Georg Thieme Verlag KG, 2020. 59. Wells P.S., Tritschler T., Kraaijpoel N., Le Gal G. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA - J. Am. Med. Assoc. American Medical Association, 2018. Vol. 320, № 15. P. 1583–1594.
Көрген адамдардың саны: 299

Түйенді сөздер:

Мақалалар санаты: Әдебиеттерге шолу

Библиографиялық сілтемелер

Исаханова С.А. Хирургиялық және травматологиялық тәжірибеде веноздық тромбоэмболия. Әдеби шолу // Ғылым және Денсаулық сақтау. 2020. 3 (Т.22). Б. 55-66. doi:10.34689/SH.2020.22.3.008

Авторизируйтесь для отправки комментариев